Data from the Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Progressing Desmoid Tumors to be Presented in an…
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company…
SHANGHAI, China, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of…
GLENDALE, Calif., Aug. 19, 2022 (GLOBE NEWSWIRE) -- THC and products similar to it are taking the world into a…
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),…
Oslo, August 19, 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second…
Oslo, Norway, 19th of August 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the…
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated…
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful…
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to…